UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------
FORM 6-K
------------
REPORT OF FOREIGN ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
March 9, 2010
------------
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
NOVO ALLE
DK-2880, BAGSVAERD
DENMARK
(Address of principal executive offices)
------------
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F
Form 20-F [X] Form 40-F [ ]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-_____________________
Novo Nordisk A/S - Share repurchase programme
On 2 February 2010 Novo Nordisk initiated its share repurchase programme in
accordance with the provisions of the European Commission's regulation no
2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.
Under the programme Novo Nordisk will repurchase B shares for an amount up to
DKK 2.0 billion in the period from 2 February 2010 to 26 April 2010.
Since the announcement as of 1 March 2010, the following transactions have been
made under the programme:
NUMBER OF AVERAGE TRANSACTION VALUE,
SHARES PURCHASE PRICE DKK
ACCUMULATED, LAST
ANNOUNCEMENT 1,811,000 694,305,064
01 March 2010 75,000 392.6800 29,451,000
02 March 2010 80,000 395.3297 31,626,376
03 March 2010 105,000 397.4695 41,734,298
04 March 2010 85,000 397.2835 33,769,098
05 March 2010 85,000 402.4701 34,209,959
ACCUMULATED UNDER THE
PROGRAMME 2,241,000 865,095,793
With the transactions stated above, Novo Nordisk owns a total of 32,512,298
treasury shares, corresponding to 5.2% of the share capital. The total amount of
shares in the company is 620,000,000 including treasury shares.
Novo Nordisk is a global healthcare company with 87 years of innovation and
leadership in diabetes care. The company also has leading positions within
haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs more than 29,300 employees in 76
countries, and markets its products in 179 countries. Novo Nordisk's B shares
are listed on the NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New
York Stock Exchange (NVO). For more information, visit novonordisk.com.
Further information:
Media: Investors:
Elin K Hansen Klaus Bulow Davidsen
Tel: (+45) 4442 3450 Tel: (+45) 4442 3176
ekh@novonordisk.com klda@novonordisk.com
Kasper Roseeuw Poulsen
Tel: (+45) 4442 4471
krop@novonordisk.com
In North America: In North America:
Sean Clements Hans Rommer
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com hrmm@novonordisk.com
Company Announcement no 13 / 2010
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf of the
undersigned, thereunto duly authorized.
Date: March 9, 2010 NOVO NORDISK A/S
---------------------------------------------------
Lars Rebien Sorensen,
President and Chief Executive Officer